Aileron Therapeutics Inc  

(Public, NASDAQ:ALRN)   Watch this stock  
Find more results for ALRN
+0.11 (1.40%)
Feb 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.79 - 8.19
52 week 7.38 - 15.48
Open 7.99
Vol / Avg. 35,654.00/24,593.00
Mkt cap 117.57M
P/E     -
Div/yield     -
EPS -1.40
Shares 14.72M
Beta     -
Inst. own 32%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.72% -129.63%
Return on average equity - -
Employees 15 -
CDP Score - -


281 Albany St
CAMBRIDGE, MA 02139-4230
United States - Map
+1-617-9950900 (Phone)
+1-617-9952410 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

Officers and directors

Joseph A. Yanchik III, Esq. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Evan Lippman Chief Financial Officer and Business Officer, Senior Vice President
Bio & Compensation  - Reuters
Manuel C. Aivado Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
D. Allen Annis Ph.D. Vice President - Biophysical and Analytical Technologies
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Director
Age: 56
Bio & Compensation  - Reuters